Silvia Maifrede,Bac Viet Le,Margaret Nieborowska-Skorska,Konstantin Golovine,Katherine Sullivan-Reed,Wangisa M. B. Dunuwille,Joseph Nacson,Michael Hulse,Lisa Beatrice Caruso,Zachary Gazze,Zhaorui Lian,Antonella Padella,Kumaraswamy Chitrala,Boris Bartholdy,Ksenia Matlawska-Wasowska,Daniela Di Marcantonio,Giorgia Simonetti,Georg Greiner,Stephen M. Sykes,Peter Valent,Elisabeth M. Paietta,Hugo F. Fernandez,Martin S. Tallman,Mark Litzow,Mark D. Minden,Jian Huang,Giovanni Martinelli,George S. Vassiliou,Italo Tempera,Katarzyna Piwocka,Neil Johnson,Grant Challen,Tomasz Skorski

Abstract:Abstract Somatic variants in TET2 and DNMT3A are founding mutations in hematological malignancies that affect the epigenetic regulation of DNA methylation. Mutations in both genes often co-occur with activating mutations in genes encoding oncogenic tyrosine kinases such as FLT3ITD, BCR-ABL1, JAK2V617F, and MPLW515L, or with mutations affecting related signaling pathways such as NRASG12D and CALRdel52. Here, we show that TET2 and DNMT3A mutations exert divergent roles in regulating DNA repair activities in leukemia cells expressing these oncogenes. Malignant TET2-deficient cells displayed downregulation of BRCA1 and LIG4, resulting in reduced activity of BRCA1/2-mediated homologous recombination (HR) and DNA-PK–mediated non-homologous end-joining (D-NHEJ), respectively. TET2-deficient cells relied on PARP1-mediated alternative NHEJ (Alt-NHEJ) for protection from the toxic effects of spontaneous and drug-induced DNA double-strand breaks. Conversely, DNMT3A-deficient cells favored HR/D-NHEJ owing to downregulation of PARP1 and reduction of Alt-NHEJ. Consequently, malignant TET2-deficient cells were sensitive to PARP inhibitor (PARPi) treatment in vitro and in vivo, whereas DNMT3A-deficient cells were resistant. Disruption of TET2 dioxygenase activity or TET2—Wilms' tumor 1 (WT1)–binding ability was responsible for DNA repair defects and sensitivity to PARPi associated with TET2 deficiency. Moreover, mutation or deletion of WT1 mimicked the effect of TET2 mutation on DSB repair activity and sensitivity to PARPi. Collectively, these findings reveal that TET2 and WT1 mutations may serve as biomarkers of synthetic lethality triggered by PARPi, which should be explored therapeutically. Significance: TET2 and DNMT3A mutations affect distinct DNA repair mechanisms and govern the differential sensitivities of oncogenic tyrosine kinase–positive malignant hematopoietic cells to PARP inhibitors.

is a synthetic lethal target in -mutant leukemia cells

SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells

3232 – TARGETING SOD1 INDUCES SYNTHETIC LETHAL KILLING OF PPM1D-MUTANT LEUKEMIA CELLS

Somatic Mutation of the Cohesin Complex Subunit Confers Therapeutic Vulnerabilities in Cancer.

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

Synthetic Essentiality of Chromatin Remodelling Factor CHD1 in PTEN-deficient Cancer

Targeting DNA polymerase β elicits synthetic lethality with mismatch repair deficiency in acute lymphoblastic leukemia

Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1

Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses

Targeting synthetic lethality between non-homologous end joining and radiation in very high-risk SHH medulloblastoma

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform

Characterization and Metabolic Synthetic Lethal Testing in a New Model of SDH-loss Familial Pheochromocytoma and Paraganglioma.

Synthetic lethality between TP53 and ENDOD1

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells

Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells